Immunophage Biomedical Co. Ltd. has identified ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, and inflammatory, autoimmune and metabolic disorders.